Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2017

View Archived Issues

ALX-1141 to enter clinical development for the treatment of osteoarthritis

Rasagiline does not add benefit to standard therapy in ALS trial

Proof-of-concept study finds potassium-channel opener ezogabine ameliorates depression

Complete disease correction using gene therapy in novel model of muccopolysaccharidosis type IIID

Phase I results for CPI-613 plus modified FOLFIRINOX in patients with metastatic pancreatic cancer

Cariprazine granted positive opinion in Europe for the treatment of schizophrenia

FDA grants rare pediatric disease designation for EF-022

AC Immune enters research collaboration with Essex Bio-Technology

EMA committee gives positive opinion to brodalumab for plaque psoriasis

eFFECTOR Therapeutics identifies novel MNK1/2 inhibitors

Emmyon patents new furostan-3-ol derivatives

NDUFS7 gene polymorphism tied to obsessive-compulsive disorder risk

University of Dundee and Corbin Therapeutics agree to identify USP15 inhibitors

Shire gives update on phase I/II study of SHP-656 for hemophilia A

Xynomic Pharma and UCSF to conduct phase II/III study of abexinostat in RCC

FDA approves Actemra as first therapy to treat giant cell arteritis

Nektar and Takeda to explore combinations of NKTR-214

Otsuka reports topline results from phase III study of tolvaptan in ADPKD

ViaCyte cleared to begin trial of PEC-Direct in U.S. and Canada

EMA committee recommends approval of Oxervate for neurotrophic keratitis

Celgene reports positive results from RADIANCE study of ozanimod

New mouse model of pulmonary hypertension induced by oxidized lipids presented

FDA approves Kevzara for rheumatoid arthritis

Zealand reports phase IIa results for dasiglucagon in type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.